The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression

Myrte K. Neijenhuis 1, Wietske Kievit 1, Ronald D. Perrone 2, Jeff A. Sloan 3, Patricia Erwin 4,5, Mohammad Hassan Murad 6, Tom J. G. Gevers 1, Marie C. Hogan 7 and Joost P. H. Drenth 1*

Abstract

Background: Little is known about determinants of quality of life (QoL) in autosomal dominant polycystic kidney disease (ADPKD). Recent studies suggest that QoL in ADPKD is determined by more factors than mere renal function. We investigated the effect of ADPKD on QoL and evaluated how QoL is affected by disease severity markers renal function, kidney volume and liver volume.

Methods: We performed a systematic review, meta-analysis and meta-regression analyses of cohort studies and randomized controlled trials investigating patient-reported QoL in adult patients with ADPKD not yet on dialysis. EMBASE, MEDLINE, and Web of Science were searched to August 2015 without language restrictions. Two investigators independently reviewed title, abstracts and full text of potentially relevant citations to determine eligibility. We compared pooled QoL summary scores of ADPKD patients using a random-effects meta-analytic model. These scores were compared with mean and age-corrected reference scores of the general population. In a meta-regression analysis, we investigated the univariate effect of renal function, kidney volume and liver volume on QoL.

Results: We included nine studies in meta-analysis including 1623 patients who completed the SF-36 questionnaire. Pooled physical (PCS) and mental component scores (MCS) of the SF-36 of individuals with ADPKD were lower than those of the reference population (45.7 vs. 50.0 and 47.8 vs. 50.0 points, both \( P < 0.001 \)). QoL of ADPKD patients remained lower after comparison with age-corrected reference values (age 35–44 year; PCS 52.2, MCS 49.9 points, both \( P < 0.05 \)). Larger liver volume negatively impacted PCS (\( P < 0.001 \)) and MCS (\( P = 0.001 \)), whereas there was no association with renal function (PCS \( P = 0.1 \), MCS \( P = 0.9 \)) and kidney volume (PCS \( P = 0.5 \), MCS \( P = 0.5 \)). Total liver and kidney volume had no impact on PCS (\( P = 0.1 \)), but did have impact on MCS (\( P = 0.02 \)).

Conclusions: QoL reported by non-dialysis patients with ADPKD is impaired compared to the general population. Large liver volume was the most important factor that diminishes QoL.

Keywords: Autosomal dominant polycystic kidney disease, Quality of life, Renal function, Kidney volume, Liver volume

* Correspondence: joostphdrenth@cs.com
1 Department of Gastroenterology and Hepatology, Radboud University Medical Center, P.O. Box 9101 code 455, 6500 HB Nijmegen, the Netherlands
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
A growing body of evidence on QoL in chronic kidney disease (CKD) suggests that quality of life (QoL) is not determined merely by renal function [1–3]. The presence of anemia and cardiovascular disease can also have substantial negative impact on QoL [1–3]. In autosomal dominant polycystic kidney disease (ADPKD), anemia [4, 5], and cardiovascular diseases [6] are less frequent compared to other kidney diseases. This suggests that other disease-specific factors may contribute to QoL impairment in ADPKD [7].

ADPKD is defined by progressive renal cyst development, leading to enlarged kidneys, kidney failure and eventually end stage kidney disease [8]. Kidney manifestations of ADPKD include acute and chronic pain, hematuria, nephrolithiasis, and cyst infection [9]. This disease is associated with a range of extrarenal manifestations, including liver cysts which occur in the majority of patients, mitral valve abnormalities and intracranial aneurysms [10]. Clinical symptoms in ADPKD seems to be a function of kidney and liver size, and are not primarily related to kidney function decline [11].

Large kidney and liver volumes compress adjacent organs and structures leading to symptoms that may impair QoL such as fullness, early satiety and pain [12, 13]. Further, it has been demonstrated that kidney enlargement occurs well before renal function decline and severe polycystic liver disease may also occur in early stage ADPKD [8, 12, 14]. This indicates that physical manifestations of ADPKD which may adversely affect QoL are present before renal function deficits are detected [8, 13].

How disease severity markers, such as renal function, kidney volume and liver volume, affect QoL in ADPKD is uncertain. Several studies showed at best very weak correlations among these variables [12–16]. Most studies included a selected population of patients with ADPKD based on either chronic kidney disease (CKD) stage or organ volumes which limits drawing robust conclusions on the relation between disease severity markers and QoL across the clinical spectrum of ADPKD. Understanding factors that impact QoL of individuals with ADPKD can guide treatment decisions and improve holistic patient-centered care beyond simply monitoring renal function [7].

This systematic review and meta-analysis investigates the effect of ADPKD on QoL. As secondary outcome, we assessed the effect of the disease severity markers renal function, kidney volume and liver volume on QoL in ADPKD.

Methods
This systematic review was conducted according to a research protocol registered in the PROSPERO international prospective register of systematic reviews (registration number CRD42015026428). We reported this systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17].

Eligibility criteria
We included studies that met the following inclusion criteria: (1) cohort studies and randomized controlled trials (RCTs); (2) adult patients >18 years, with a diagnosis of ADPKD [18] and; (3) use of a patient-reported outcome to reflect QoL. We excluded studies that (1) used a patient-reported outcome without summary score of individual questions, (2) studies that investigated QoL with a one-item visual analogue scale (VAS) only as it often provides insufficient QoL information [19], (3) longitudinal intervention studies that provided no baseline QoL scores and, (4) studies that did not report original data.

Search strategy
A medical librarian (P.E.) developed and executed a systematic search combining the search terms and Medical Subject Headings for ‘ADPKD’ and ‘renal function’ or ‘kidney volume’ or ‘liver volume’ or ‘quality of life’ in the electronic databases of EMBASE, MEDLINE, and Web of Science. Letters to the editor, editorials and case reports were excluded. Additional file 1: Table S1 provides an example of one full electronic search. We searched for conference abstracts in abstract books of the American Society of Nephrology (ASN), World Congress of Nephrology (WCN) and the European Renal Association – European Transplant and Dialysis Association (ERA-EDTA) published between August 2012 and August 2015 and unpublished studies in the database of clinicaltrials.gov. Reference lists of included articles and relevant reviews were screened for additional leads. Two investigators (M.N. and M.H.) independently reviewed title and abstracts to determine eligibility. Disagreements between M.N and M.H. were included for full text review. Subsequently, both investigators screened full text of eligible studies and disagreement between M.N and M.H. was resolved by discussion with a third author (T.G.). Corresponding authors of original articles were contacted for additional information if needed. Cohen’s kappa was calculated as measure of agreement on study selection. A value between 0.40–0.59 was considered as fair agreement, 0.60–0.74 as good agreement and 0.75 or higher as excellent agreement [20].

Quality assessment
Since there is no standard tool available to assess the risk of bias for uncontrolled studies, we used items derived from the Newcastle-Ottawa Scale to assess risk of
bias on study and outcome level [21]. We scored the categories (1) study population selection; (2) completeness of reported results; (3) used patient-reported outcome instrument; (4) recall period and; (5) response rate as low or high risk of bias followed by an overall conclusion of the risk of bias (low, moderate or high risk of bias) as judged by two independent reviewers.

**Outcome**

Primary outcome was summary QoL score measured with a patient-reported outcome instrument at baseline. We included studies in meta-analysis and meta-regression that used a patient-reported outcome measure that was used in 3 or more studies [22]. Scores of individuals with ADPKD were compared with reference values if available.

We expected that the SF-36 was used in most studies, as it is the most frequently used patient-reported outcome worldwide and is often used in kidney studies [23, 24]. The SF-36 is a generic QoL measure that composes of eight domains (physical functioning, role-physical, bodily pain, general health, social functioning, vitality, role-emotional, and mental health) that can be summarized in two composite scales; the physical component scale (PCS) and mental component scale (MCS) [25]. These summary scores can reduce type I errors by avoiding multiple testing and can distinguish better between different health state levels than the eight separate domains [26]. A higher PCS or MCS score indicate a better QoL. Population-based reference values for both component scales are set to 50 points with a standard deviation of 10 points [27]. We calculated component scores of the SF-36 using US norm values, as previous studies showed a similar impact of chronic diseases on QoL across different countries [28].

**Data extraction**

M.N. extracted data of the included articles using a standardized data collection form to record (1) study characteristics: first author, year of publication, country of origin, study design and number of participants; (2) patient characteristics: age, gender, chronic kidney disease (CKD) stage as defined by KDIGO [29], mean renal function defined as (estimated) GFR in ml/min/1.73m², median kidney and liver volume measured with volumetric software or ellipsoid formula (kidney volume only); (3) QoL data: baseline summary scores of patient-reported outcome instruments. For studies that presented only serum creatinine as measure of renal function, we calculated the eGFR with the chronic kidney disease epidemiology collaboration (CKD-EPI) formula and Modification of Diet in Renal Disease (MDRD) formula [30]. Total liver and kidney volume was calculated by summing liver and kidney volumes. In RCTs, baseline QoL scores of both placebo and intervention groups of RCTs were pooled. QoL data of subgroups stratified by renal function was handled separately. Summary scores were calculated when the original authors used a scoring algorithm which was different from the official published scoring manual. W.K. reviewed the complete dataset for completeness and accuracy.

**Data analysis**

To calculate the effect of ADPKD on QoL, we performed a pre-specified analysis using a random-effects meta-analytic model of DerSimonian and Laird [31]. The random effect model is used if large heterogeneity is expected and adjusts for differences in study size. Heterogeneity was assessed using I² statistics and a cutoff value of I² > 50% was considered as substantial heterogeneity [32]. When population-based reference values of included patient-reported outcomes were available, we compared whether the pooled mean scores of ADPKD patients were significantly different compared to the general population with an independent t-test. When the pooled mean of ADPKD patients was significantly lower than the general population, we compared the pooled means with age-corrected values to assess whether this difference remained significant. Additional sensitivity analyses including high quality studies only were performed to assess the influence of study quality.

To explore the effect of disease severity markers on QoL, we performed a pre-specified univariate meta-regression analysis in which the dependent variable was QoL score (PCS or MCS) and the independent variables were renal function, kidney volume, liver volume and total liver and kidney volume. As additional exploratory analysis, we performed the primary meta-regression excluding studies with severe liver involvement (defined as median liver volume > 3000 mL, based on a previous published classification [14]). Kidney and liver volumes have a skewed distribution and were logarithmically transformed. If a study provided no standard deviation (SD), standard error (SE) or interquartile range (IQR) of the summary QoL score, we imputed SD from the mean SD of other included studies. As a sensitivity analysis, we compared the results of the meta-regression of eGFR calculated with the CKD-EPI with eGFR calculated with the MDRD formula. Analyses were performed using the statistical program OpenMetaAnalyst [33]. For all analyses, P < 0.05 was considered statistically significant.

**Results**

From a total of 373 unique articles identified by our systematic search, 11 studies matched our inclusion criteria [13, 15, 16, 34–41]. Figure 1 shows the PRISMA flow
diagram with specified reasons for exclusion. There was excellent agreement between the two reviewers on study selection (Cohen’s Kappa 0.89). We found only two studies that investigated QoL in patients with ADPKD on dialysis \( n = 108 \) and \( n = 5 \) respectively, which prevented a reliable meta-analysis in this subgroup [15, 34]. We contacted eight authors for additional information that was not published in the original articles and received relevant data from six of them [15, 34–36, 38, 39]. Four studies included a mixed population of patients with isolated polycystic liver disease (ADPLD) and polycystic liver disease as extrarenal manifestation of ADPKD [35, 36, 39, 40]. For all these studies, we obtained separate ADPKD group data by contacting the authors.

Eight studies used the SF-36 as patient-reported outcome and one study used the KDQOL-SF1.3, a combined questionnaire of the SF-36 and 43 kidney disease-specific questions. The gastrointestinal symptom scale was administered together with the SF-36 or EQ-5D in three studies [36, 40, 41]. As there is no validated total score of the gastrointestinal symptoms scale and the EQ-5D was used in only two studies, this resulted in exclusion of two studies for meta-analysis [40, 41]. Other patient-reported outcomes administered together with the SF-36 were used in less than three studies and were also excluded from further analyses (see Table 1). After applying these eligibility criteria, only studies that used SF-36 data were eligible for inclusion.

**Characteristics and quality of included studies**

Table 1 describes the characteristics of the nine studies included in meta-analysis [13, 15, 16, 34–39]. The majority were longitudinal interventional studies \( n = 7 \), including three randomized controlled trials. The nine studies included 1623 non-dialysis patients. At least 753 patients had CKD stage 1–2 and 478 CKD 3–4. There was insufficient individual patient data on the renal function of 363 patients to distinguish between CKD stage 1–4. One study \( n = 29 \) did not provide renal function of the included patients [37], resulting in 1594 available patients to assess the impact of renal function on QoL. Seven studies reported kidney volumes \( n = 1238 \) of the included patients [13, 15, 16, 35–37, 39]. Five studies reported liver volume \( n = 1057 \), [13, 15, 35, 36, 39] including four studies with severe polycystic liver disease patients (median liver volume > 3000 mL) [15, 35, 36, 39]. The SD of the PCS and MCS was imputed in four studies. Patients were on average 44 years and 45% was male. Pooled mean (e)GFR was 58 mL/min/1.73m² (95% CI 47 to 69), kidney and liver volumes were respectively 1465 mL (95% CI 1146 to 1784) and 3599 mL (95% CI 3010 to 4187). This indicates enlargements of approximately 4 and 2.5 times compared to normal kidneys (300 mL for females and 400 mL for males) and livers (1400 mL for females, 1700 mL for males), respectively.

A detailed quality assessment of the studies is presented in Additional file 1: Table S2. There was a low risk of bias in the majority of the studies \( n = 8 \) and one study was rated as having a high risk of bias (insufficient information on study population selection and very low response rate).

**QoL in ADPKD**

Figure 2 shows the results of the pooled SF-36 scores of the PCS (A) and MCS (B). The mean PCS of individuals...
### Table 1 Characteristics of included studies

| First author, year | Country of origin | Study design | Subgroup | Patients (n), completed PRO% | Age (mean ± SD) | Gender (% male) | CKD stage | (e)GFR ml/min/1.73m² (mean ± SD) | Kidney volume (mL), (mean ± SD or median [IQR]) | Liver volume (mL), (mean ± SD or median [IQR]) | Patient-reported outcome measure |
|-------------------|------------------|--------------|----------|-----------------------------|----------------|----------------|-----------|---------------------------------|---------------------------------------------|-----------------------------------------------|---------------------------------|
| Barros et al., 2011 [34] | Brazil | Cross-sectional | Non-dialysis | 33 (100) 37 ± 12 | 24 | 1–4 | 69 ± NR | NR | NR | State Trait Anxiety Inventory, Beck Depression scale, SF-36 |
| Hogan et al., 2010 [35] | USA | Randomized controlled trial | All patients | 34 (100) 50 ± 9 | 24 | 1–4 | 61 ± 22 | 852 (486–1430) | 4906 (3258–8404) | SF-36 |
| Keimpema et al., 2009 [36] | Netherlands | Randomized controlled trial | All patients | 32 (97) 51 ± 9 | 13 | 1–4 | 64 ± 25 | 872 (502–1551) | 4906 (3380–6416) | SF-36, Gastrointestinal symptom scale |
| Lee et al., 2003 [37] | USA | Longitudinal observational study | All patients | 29 (28) 46 ± 14 | 24 | 1–4 | NR | 2276 (NR) | NR | SF-36 |
| Miskulin et al., 2014 [13] | USA | Randomized controlled trial | All patients | 1043 (99) 42 ± NR | 50 | 1–4 | 68 ± NR | 1215 ± NR | 1958 ± NR | SF-36, Modified version of the Wisconsin Brief pain survey |
| Rizk et al., 2009 [16] | USA | Longitudinal observational study | All patients | 152 (100) 44 ± 10 | 40 | 1–4 | 65 ± 33 | 937 ± 883 | NR | SF-36 |
| Simms et al., 2015 [38] | United Kingdom | Cross-sectional | All patients | 139 (100) 49 ± 16 | 48 | 1–4 | 59 ± 33 | NR | NR | KDQOL-SF1.3, Patient health questionnaire (PHQ-9), multidimensional scale of perceived social support (MSPSS), Sheffield ADPKD psychosocial risk instrument (Sheffield ADPKD PSRI) SF-36 and self-made symptom scale |
| Suwabe et al., 2013 [15] | Japan | Longitudinal observational study | Non-dialysis | 111 (100) 52 ± 12 | 40 | 1–4 | 30 ± NR | 3308 ± 2566 | 3841 ± 3551 |
| Temmerman et al., 2014 [39] | Belgium | Longitudinal observational study | All patients | 50 (100) 51 ± 9 | 10 | 1–4 | 58 ± 24 | 1126 (586–1806) | 4918 (3942–6360) | SF-36, Polycystic liver disease complaint-specific assessment (POLCA) |

*CKD chronic kidney disease stage, NA not applicable, NR not reported, PRO patient reported outcome, SD standard deviation *Calculated based on serum creatinine with CKD-EPI formula *Kidney and liver volumes only measured in patients with eGFR >45 ml/min
with ADPKD was 45.7 points (95% CI 42.7 to 48.7), although there was significant heterogeneity (I² 95.4%, P < 0.001). This was significantly different from the mean score of the general population (PCS 50 points 95% CI 49.6 to 50.4, P < 0.001). On the MCS, patients scored 47.8 points (95% CI 45.7–49.8), with again large heterogeneity (I² 90.7%, P < 0.001). Also this score was lower compared to the general population (PCS 50 points, 95% CI 49.6 to 50.4, P < 0.05). Compared with age-corrected reference values (age 35–44 year; (PCS 52.2, 95% CI 51.5 to 52.8 and MCS 49.9 points, 95% CI 49.1 to 50.7, both P < 0.001), QoL of ADPKD patients remained significantly lower. Sensitivity analysis including high quality studies only showed no differences in pooled scores compared to the analyses including all studies.

The relationship between markers of disease severity and QoL in ADPKD patients

The relationship of the disease severity markers renal function, kidney volume, liver volume and total liver and kidney volume on PCS is shown in Fig. 3. Larger liver volume negatively impacted PCS (β = −10.7, 95% CI -16.4 to −5.0, P < 0.001). We observed no significant effect of renal function (β = 0.1, 95% CI -0.03 to 0.2, P = 0.1), kidney volume (β = 2.5, 95% CI -5.2 to 10.3, P = 0.5) and total liver and kidney volume (β = −10.2, 95% CI -22.3 to 1.8, P = 0.10). On MCS, larger liver volume (β = −4.7, 95% CI -7.5 to −1.8, P = 0.001) and total liver and kidney volume (β = −5.6, 95% CI -10.0 to −1.1, P = 0.02) had significant impact, while renal function (β = −0.005, 95% CI -0.08 to 0.07, P = 0.9) and kidney volume (β = −1.5, 95% CI -5.6 to 2.5, P = 0.5) did not (Additional file 2: Figure S1). Sensitivity analyses showed similar results using the MDRD formula to calculate eGFR or when low quality studies were excluded.

In studies with mild to moderate liver involvement (median liver volume ≤ 3000 mL), renal function did have a negative impact on PCS (β = 0.1, 95% CI 0.05 to 0.2, P = 0.02), but there was no effect of kidney volume (β = −7.8, 95% CI 23.2 to 7.7, P = 0.3; Fig. 4). On the MCS, neither renal function (β = −0.02, 95% CI -0.11 to 0.08, P = 0.8) nor kidney volume (β = −2.9, 95% CI -10.2 to 4.3, P = 0.4) had impact (Additional file 3: Figure S2).

Discussion

We show that ADPKD negatively impacts QoL, particularly through the effect of the disease on parameters of the physical domain. Individuals with ADPKD had lower PCS and MCS compared to population-based reference values. We found large heterogeneity across QoL of individuals with ADPKD. In the primary meta-regression performed to explain this heterogeneity, larger liver volume, but not renal function and kidney volume, correlated with lower physical and mental components of health status in ADPKD. However, after exclusion of studies of patients with large liver volumes, lower renal function was also correlated with lower PCS.

Large liver volume had a negative effect on QoL in ADPKD, indicating that liver volume is an important parameter that should be accounted for when investigating QoL in this population. However, the strong female predominance in severe polycystic liver disease studies (74 vs. 53%, P < 0.001) and inclusion of slightly older patients (mean age 51 ± 10 vs. 43 ± 12 year, P = 0.24) in studies with mild to moderate liver involvement can also contribute to QoL impairment in these patients [27]. Comparing general reference values of younger males (35–44 years) with older females (45–54 years), resulted in a mean difference of 4.5 and 0.2 points for PCS and MCS, respectively. The loss of QoL in the liver volume meta-regression analysis was larger than these differences (β = −10.7 points per logarithm for PCS and β = −4.7 for MCS), suggesting an independent additional effect of liver volume on QoL.
Our exploratory analysis suggests that QoL declines during progression towards CKD stage 5 in patients without severe polycystic liver disease. This indicates that renal function is also an important factor of QoL in ADPKD, but this effect was negated by the strong impact of liver volume in the total group. An independent patient data analysis with correction for liver volume is necessary to draw definitive conclusions about the role of renal function and kidney volume on QoL.

A previous study showed that patients with larger kidney volume reported more pain that impacted their daily life compared to patients with smaller kidneys [13]. We did not find a significant impact of kidney volume on QoL, possibly because only a limited number of studies in our meta-analysis included patients with large kidney volumes. A large observational study including 450 ADPKD patients of CKD stages 1–4 (DIPAK) is currently being conducted in the Netherlands. This study may reveal whether large kidney volume contributes to a decrease in QoL.

A strength of this study is that we conducted this systematic review by rigorously following a published protocol with pre-specified analyses. Meta-regression including disease severity markers provides insight into the heterogeneous results of QoL found in earlier studies.
Our study comes with a number of limitations. First, not all studies reported values of all disease severity markers, which limited the number of studies included in our meta-regression analysis. Furthermore, not all potential modifiers of QoL in ADPKD could be included in this study. Earlier studies have shown that comorbidity, the use of pain medication, presence of a cerebral aneurysm, and lower education levels are associated with lower QoL in this population [16, 38]. Two qualitative studies showed that genetic guilt also might be an important factor that influences QoL [42, 43]. The lack of detail in the articles under study precluded systematic analysis of these factors.

Secondly, part of heterogeneity in QoL might also be explained by study design. Most included studies were intervention studies. Patients involved in these studies do not resemble the general ADPKD patient population. QoL of patients participating in intervention studies was generally lower compared to patients from observational studies, likely due to the reality that most interventional studies have included patients with larger livers. However, the large variability in disease severity markers enabled us to thoroughly investigate the impact of these factors on QoL in individuals with ADPKD.

Third, we could include only QoL data collected with a generic patient-reported outcome, which is likely less sensitive to detect disease burden than disease-specific measures [44]. On the other hand, an unpublished global observational study of 3409 individuals with ADPKD showed that the PCS of the SF-12, a short version of the SF-36, could differentiate QoL between CKD 1 and CKD 3a, while the disease-specific ADPKD Impact Scale could differentiate CKD 1 from CKD stage 3b [45]. This suggests that the PCS distinguishes between individuals with ADPKD in a slightly earlier phase than the disease-specific ADPKD Impact Scale. The MCS of the SF-12 was unable to differentiate between CKD 1 and other disease stages, indicating that this component score is insensitive to change in this disease population.

This systematic review on QoL in ADPKD clearly identified knowledge gaps. Data on QoL in patients with ADPKD and more advanced stages of CKD were insufficient to be assessed. As liver volume appears to impact QoL, clinicians should check liver disease severity periodically and consider liver volume reducing therapies in severe hepatomegaly as a strategy to improve patients’ wellbeing. Indeed, research shows that reduction of liver volume with somatostatin analogues improves QoL in severe polycystic liver disease [46]. However, currently data is lacking on the effect of other therapies on QoL. In patients without severe polycystic liver disease, QoL was negatively impacted by renal function. Vasopressin V2 receptor antagonists slow renal function decline, but additional studies should investigate whether the possible positive effect on QoL is counteracted by side effects such as aquarexia.

Conclusion

In conclusion, there is limited representative data available on the impact of disease severity markers on QoL in ADPKD. Existing data showed that QoL of non-dialysis ADPKD patients is impaired compared to the general population. Large liver volume was the most important factor that diminishes QoL.

Additional files

| Additional file 1: Table S1. Example of the search strategy (MEDLINE). | Table S2. Risk of bias assessment QoL studies. (DOCX 18 kb) |
| Additional file 2: Figure S1. Meta-regression analysis of the mental component score of the SF-36 with the factors (A) (e)GFR (ml/min/1.73m²) (B) Kidney volume in mL, (C) liver volume in mL and (D) total liver and kidney volume in mL. (TIFF 67 kb) |
| Additional file 3: Figure S2. Meta-regression analysis of the mental component score of the SF-36 with the factors (A) eGFR (ml/min/1.73m²) and (B) Kidney volume in studies with mild to moderate liver involvement. (TIFF 54 kb) |

Abbreviations

- (e)GFR: (estimated) glomerular filtration rate; 95% CI: 95% confidence interval; ADPKD: Autosomal dominant polycystic kidney disease; ADPLD: Autosomal dominant polycystic liver disease; ASN: American society of nephrology; CKD: Chronic kidney disease; CKD-EPI: Chronic kidney disease – epidemiology collaboration equation; ERA-EDTA: European renal association – European transplant and dialysis association; IQR: Interquartile range; MCS: Mental component score; MDRD: Modification of diet in renal disease equation; PCS: Physical component score; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; QoL: Quality of life; SD: Standard deviation; SE: Standard error; WCN: World congress of nephrology

Acknowledgements

We would like to sincerely thank the following investigators for sharing additional data to enable this manuscript: L. van Keimpema, MD, PhD, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; M. Kirsztajn, MD, PhD, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; M. C. Hogan, MD, PhD, Mayo Clinic Rochester (MN), US; R. Simms, MD, University of Sheffield Medical School, Sheffield, United Kingdom; T. Suwabe, MD, Toranomon Hospital, Tokyo, Japan; F. Temmerman, MD, PhD, University Hospital Leuven, Leuven, Belgium.

Funding

This study received funding from the Mayo Translational Polycystic Kidney Disease Center (NIDDK P30 DK090728). Myrte K. Neijenhuis received a Koff PhD Fellowship Abroad Grant from the Dutch Kidney Foundation. The funders had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.

Availability of data and materials

All datasets analyzed in this systematic review are referenced in the manuscript and Additional files.

Authors’ contributions

Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work. MN: research idea, study design, data acquisition, data analysis and interpretation and drafting the manuscript; WK: research idea, study design, data analysis and interpretation; RP: research idea, drafting the manuscript; JS: research idea, study design, drafting the manuscript; PE: data acquisition, critically revision of the manuscript; MM: study design, data analysis and interpretation, statistical
analysis; TG: research idea, study design, data analysis and interpretation; MH: research idea, data acquisition, drafting the manuscript; JD: supervision and mentorship, drafting the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Gastroenterology and Hepatology, Radboud University Medical Center, P.O. Box 91010, 6500 HB Nijmegen, the Netherlands. 2Radboud Institute for Health Science, Radboud University Medical Center, Nijmegen, the Netherlands. 3Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA, USA. 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 5Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA. 6Robert D. and Patricia E. Kern Center for Sciences Research, Mayo Clinic, Rochester, MN, USA. 7Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Received: 19 July 2016 Accepted: 10 May 2017
Published online: 25 May 2017

References
1. Perlman RL, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45(4):658–66.
2. Kusek JW, et al. Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American Study of Kidney Disease and Hypertension Trial. Am J Kidney Dis. 2002;39(3):13–24.
3. Chow FY, et al. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis. 2003;41(3):596–604.
4. Eckardt KU, et al. Erythropoietin in polycystic kidneys. J Clin Invest. 1989;84(4):1160–6.
5. Chandra M, et al. Serum immuno-reactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1989;51(1):26–9.
6. Spithoven EM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29(Suppl 4):iv15–iv21.
7. Perrone RD, et al. Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2013;62(6):1046–57.
8. Bae KT, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(6):146–9.
9. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–85.
10. Torres VE, Harris PC, Pinson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301.
11. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1(1):148–57.
12. Wijnands TF, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int. 2014;34(10):1578–83.
13. Miskulin DC, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1–4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214–26.
14. Hogan MC, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015;13(1):155–64, e6.
15. Suwabe T, et al. Quality of life of patients with ADPKD – Toranomon PKD QOL study: cross-sectional study. BMC Nephrol. 2013;14(1):179.
16. Röck D, et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009;4(3):560–6.
17. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
18. Pei Y, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205–12.
19. Kim J, et al. Correlations between electrically quantified pain degree, subjectively assessed visual analogue scale, and the McGill pain questionnaire: a pilot study. Ann Rehabil Med. 2014;38(5):665–72.
20. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360–3.
21. Wells GA, S.B., O’Connell D, Petersen J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
22. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–73.
23. Contopoulos-Ioannidis DG, et al. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ. 2009;338:a3006.
24. Fukushima S, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64(5):1903–10.
25. Ware JE Jr, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(Suppl A):S264–79.
26. Ware JE Jr, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1167–70.
27. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user’s manual. Boston: Health institute, New England Medical Center, 1994.
28. Alonso J, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283–98.
29. Levey AS, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.
30. Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
32. Guyatt GH, et al. GRADE guidelines: 7. Rating the quality of evidence−inconsistency. J Clin Epidemiol. 2011;64(12):1294–302.
33. Wallace, B.C., Issa J. Dahabreh, Thomas A. Trikalinos, Joseph Lau, Paul Trow, and Christopher H. Schmid, Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. J Stat Softw. 2012;49(5):1
34. Contopoulos-Ioannidis DG, et al. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ. 2009;338:a3006.
35. Hogan MC, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney disease. J Bras Nefrol. 2011;33(2):120–8.
36. van Keimpema L, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2010;21(6):1052–61.
37. van Keimpema L, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2010;21(6):1052–61.
38. van Keimpema L, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2010;21(6):1052–61.
39. van Keimpema L, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2010;21(6):1052–61.
39. Temmerman F, et al. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). J Hepatol. 2014;61(5):1143–50.

40. Chrispijn M, et al. Everolimus does not further reduce polycystic liver volume when added to long-acting octreotide: Results from a randomized controlled trial. J Hepatol. 2013;59(1):153–9.

41. Gevers TJ, et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int. 2015;35(5):1607–14.

42. Baker A, et al. Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians. Clin Kidney J. 2015;8(5):531–7.

43. Tong A, et al. A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrol Dial Transplant. 2015;30(5):790–800.

44. Revicki D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9.

45. D. Oberdhan, A.B.C., R. D. Perrone, A. L. Serra, J. C. Cole, W. Zhou, H. Krasa, J. Blais, F. S. Czerwiec, Patient Reported Health Related Quality of Life in ADPKD: Analysis from OVERTURE. American Society of Nephrology - Kidney Week 2015, San Diego, US, SA-PO871, 2015.

46. Neijenhuis MK, et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment Pharmacol Ther. 2015;42(5):591–8.